Evidence map›Paper›PMID 33751579›Full record

ReviewBritish journal of pharmacology2021

Clinical applications for exosomes: Are we there yet?

Dany Perocheau, Loukia Touramanidou, Sonam Gurung, Paul Gissen, Julien Baruteau

Abstract readReview
In one paragraph

Review in British journal of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Exosomes and solid cancer therapy: where are we now?Medical oncology (Northwood, London, England) · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Exosomes from Different Sources in Promoting Wound Healing.Recent advances in drug delivery and formulation · 2025
    Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dany PerocheauGenetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, UK.
Loukia TouramanidouGenetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, UK.
Sonam GurungGenetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, UK.
Paul GissenGenetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, UK.
Julien BaruteauGenetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0003-0582-540X

Funding

London Advanced Therapy / Confidence in Collaboration award 2CiC017Medical Research Council MR/T008024/1MRC Clinician Scientist FellowshipNIHR Great Ormond Street Hospital Biomedical Research CentreNutricia Metabolic Research Grant NAUnited Kingdom Research Council Innovate UK Biomedical Catalyst award 14720United Kingdom Research Council Innovate UK Biomedical Catalyst 14720
6 · The paper itself

Abstract

Exosomes are a subset of extracellular vesicles essential for cell-cell communication in health and disease with the ability to transport nucleic acids, functional proteins and other metabolites. Their clinical use as diagnostic biomarkers and therapeutic carriers has become a major field of research over recent years, generating rapidly expanding scientific interest and financial investment. Their reduced immunogenicity compared to liposomes or viral vectors and their ability to cross major physiological barriers like the blood-brain barrier make them an appealing and innovative option as biomarkers and therapeutic agents. Here, we review the latest clinical developments of exosome biotechnology for diagnostic and therapeutic purposes, including the most recent COVID-19-related exosome-based clinical trials. We present current exosome engineering strategies for optimal clinical safety and efficacy, and assess the technology developed for good manufacturing practice compliant scaling up and storage approaches along with their limitations in pharmaceutical industry.

Indexed as

COVID-19ExosomesExtracellular VesiclesDrug Delivery SystemsHumansSARS-CoV-2cancerexosomeimmunomodulationinfectious diseasesinflammationmanufacturingtherapeutics

Identifiers

PMID33751579
PMCPMC8432553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.